Gemina Labs has developed and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals. Our tests are fast, affordable and accurate, and easily self-administered providing consumers with direct solutions where they need them.
"The Gemina Labs dual affinity probe technology establishes a flexible and novel approach to attaching functional biomolecules to diverse surfaces …The technology has been evaluated by Paragreen and offers significant potential competitive advantages including increased performance and cost efficiency in applications ranging from human and veterinary diagnostics to environmental testing, food safety, agriculture, and industrial bioprocessing.”
We're building a new category of biosensors - moving diagnosis out of the clinic and into the hands of the patient and user...
Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.
Physical Science Innovations CEO
Scientific Research Capital CEO
IP Group CFO, COO
Index IT Partnership CFO
Founder Eco Mine Technologies
M.Eng, UBC in surface chemistry
Assoc. Prof Sauder School of Business
Founder of NatureBank Asset Management
Deputy Director James Martin Institute, Oxford
20 years of experience with the British Government. Extensive national and international relationships. Served as CEO and director of companies including threat detection specialist, Patriot One (TSX: PAT)
7 years with PWC
B.Sc in pharmaceutical sciences
40 years in life science product innovation, including: Amersham, J&J (Ortho Clinical Diagnostics) IGEN (Roche lead IVD platform) Philips Healthcare
PhD in molecular biology & immunology(University of Zurich)
14 years in biotechnology companies
A senior engineering lead and product development executive, with a career spent in the medical device space.
PhD in management information systems(U Washington)
Research fellow in sustainable data systems, UBC
Professor and Turing Fellow, Newcastle University. Career in vitro diagnostic product development (Swiss Precision, Unilever) including pioneering the development of the Clearblue lateral flow assay pregnancy test. At Unilever he led the Healthy Aging program for integrated technologies for lifestyle interventions.
Executive with thirty years experience in Fortune 100 companies in the development of life science technologies. Worked in product development with Amersham, Kodak Diagnostics, Boehringer Mannheim and others. Background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging.
CEO and founder of RAPivD, a scientific R&D company focused on diagnostics platforms such as lateral flow, electrochemical and op to electrical systems. He began his career with Unilever before transferring to the UK’s NationalPhysics Laboratory, building a bio sensing patent portfolio before spinning out Argento Diagnostics.Subsequently, Rob has held seniorBoard positions (CEO, CTO, COO) with a slate of UK diagnostic companies and has recently served as an adviser to the UK Health Service in respect of scale-up manufacturing for COVID rapid testing.
Former COO of Swiss PrecisionDiagnostics, the current manufacturers of the Clear blue lateral flow assay products. SPDis 50% owned by Abbott Labs and 50% owned by P&G. Brian took on the COO role after 5years as managing director of the SPD’s UK subsidiary.
Early career as a biotech analyst, launched career as an executive and board positions in biotechnology companies in Canada and the US. Responsible for commercial transactions with Alexion Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, and JDR.